James Godfrey, Matthew Mei, Lu Chen, Joo Y Song, Victoria Bedell, Elizabeth Budde, Saro Armenian, Sandrine Puverel, Liana Nikolaenko, Robert Chen, Shari Daniels, Neena Kennedy, Lacolle Peters, Steven T Rosen, Stephen J Forman, Leslie L Popplewell, Larry W Kwak, Alex F Herrera
Outcomes after programmed death-1 (PD-1) blockade in B-cell lymphomas are disappointing with few durable responses. Histone deacetylase inhibitors exhibit favorable immunomodulatory effects and demonstrate synergistic anti-tumor immune responses with anti-PD-1 therapy in preclinical models. We, therefore, developed a phase I study to evaluate the safety and preliminary efficacy of pembrolizumab with vorinostat in relapsed/refractory B-cell lymphomas. Patients were treated in a dose-escalation cohort using a Rolling 6 design followed by an expansion cohort at the recommended phase II dose (R2PD)...
February 1, 2024: Haematologica